1. GPCR/G Protein
  2. Angiotensin Receptor
    Prostaglandin Receptor
  3. Tranilast

Tranilast (Synonyms: MK-341; SB 252218)

Cat. No.: HY-B0195 Purity: 99.46%
Handling Instructions

Tranilast (MK-341) acts as an anti-atopic agent. Tranilast suppresses production of prostaglandin D2 (PGD2, IC50= 0.1 mM). Tranilast sodium exhibits anti-inflammatory and immunomodulatory effects. Tranilast sodium antagonizes angiotensin II and inhibits its biological effects in vascular smooth muscle cells.

For research use only. We do not sell to patients.

Tranilast Chemical Structure

Tranilast Chemical Structure

CAS No. : 53902-12-8

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply Now  
Solution
10 mM * 1 mL in DMSO USD 66 In-stock
Estimated Time of Arrival: December 31
Solid + Solvent
10 mM * 1 mL
ready for reconstitution
USD 66 In-stock
Estimated Time of Arrival: December 31
Solid
10 mg USD 60 In-stock
Estimated Time of Arrival: December 31
50 mg USD 96 In-stock
Estimated Time of Arrival: December 31
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 4 publication(s) in Google Scholar

Other Forms of Tranilast:

Top Publications Citing Use of Products

    Tranilast purchased from MCE. Usage Cited in: Pharmacol Res. 2017 Nov;125(Pt B):150-160.

    The IL-33 production in different treatment groups is determined in rat skin by immunohistochemistry assay.
    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Tranilast (MK-341) acts as an anti-atopic agent. Tranilast suppresses production of prostaglandin D2 (PGD2, IC50= 0.1 mM). Tranilast sodium exhibits anti-inflammatory and immunomodulatory effects[1]. Tranilast sodium antagonizes angiotensin II and inhibits its biological effects in vascular smooth muscle cells[2].

    IC50 & Target

    PGD2

    0.1 mM (IC50)

    Angiotensin II

     

    In Vitro

    Tranilast exhibits significant immunomodulatory activity inhibiting Endotoxin-induced prostaglandin E2 (PGE2; IC50=~1-20 μM), thromboxane B2 (IC50=~10-50 μM), (TGF-β1; IC50=~100-200 μM), and IL-8 (IC50=~100 μM) formation. A23187-induced monocyte leukotriene C4 or PGE2 formation is inhibited by Tranilast at IC50s of 10-40 μM and 2-20 μM, respectively[3].
    Tranilast (10-200 μM) exhibits the anti-proliferative effect in a dose-dependent manner in both MCF-7 and MDA-MB-231 cell lines. Tranilast also (10-200μM) enhances the anti-tumor effects of Tamoxifen (1-20 μM) on human breast cancer cells in vitro[4].
    Tranilast (12.5, 25, 50, 100 μg/mL; 72 hours) inhibits proliferation of HDMECs[5].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Proliferation Assay[4]

    Cell Line: MCF-7 and MDA-MB-231 cells
    Concentration: 10, 20, 50, 100, and 200 μM
    Incubation Time: 48 hours
    Result: Anti-proliferative effect in a dose-dependent manner in both cell lines.

    Cell Viability Assay[5]

    Cell Line: Human dermal microvascular endothelial cells (HDMECs)
    Concentration: 12.5, 25, 50, 100 μg/mL
    Incubation Time: 72 hours
    Result: IC50 value was 44.3 μg/mL (136 μM).
    In Vivo

    Tranilast (300 mg/kg; administered orally twice a day for 3 days) dose-dependently suppresses angiogenesis in mice[5].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Nine-week-old male C57BL/6 mice[5]
    Dosage: 300 mg/kg
    Administration: Administered orally twice a day for 3 days
    Result: Suppressed the VEGF-induced angiogenesis in matrigel; 58% of significant suppression was observed at a dose of 300 mg/kg.
    The ED50 value and 95% confidence limits were 165 mg/kg and 162±169 mg/kg, respectively.
    Clinical Trial
    Molecular Weight

    327.33

    Formula

    C₁₈H₁₇NO₅

    CAS No.
    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 50 mg/mL (152.75 mM; Need ultrasonic)

    H2O : 10 mg/mL (30.55 mM; ultrasonic and adjust pH to 12 with NaOH)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.0550 mL 15.2751 mL 30.5502 mL
    5 mM 0.6110 mL 3.0550 mL 6.1100 mL
    10 mM 0.3055 mL 1.5275 mL 3.0550 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Add each solvent one by one:  30 % SBE-β-CD

      Solubility: 5 mg/mL (15.28 mM); Suspended solution; Need ultrasonic

    • 2.

      Add each solvent one by one:  1.5% CMC-Na/saline water

      Solubility: 4 mg/mL (12.22 mM); Suspended solution; Need ultrasonic

    • 3.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.5 mg/mL (7.64 mM); Clear solution

    • 4.

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

      Solubility: 2.5 mg/mL (7.64 mM); Suspended solution; Need ultrasonic

    • 5.

      Add each solvent one by one:  10% DMSO    90% corn oil

      Solubility: ≥ 2.5 mg/mL (7.64 mM); Clear solution

    *All of the co-solvents are provided by MCE.
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email address *

    Phone number *

     

    Organization name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Tranilast
    Cat. No.:
    HY-B0195
    Quantity:
    MCE Japan Authorized Agent: